CTLA4 and type 1 diabetes mellitus: The risk of ICI-T1DM varies by therapeutic class, with the highest frequency observed under PD-1/PD-L1 plus CTLA-4 dual therapy, followed by PD-1 monotherapy, PD-L1 monotherapy, and CTLA-4 monotherapy (15).